[Edaily Reporter YU JIN-HEE ] Ensol Biosciences (Ensol Bio), a leading player in the KONEX market, is expanding its reach beyond treatments for degenerative diseases into the fields of cancer and brain disorders. The company’s largest shareholder is injecting additional funds, further bolstering confidence in the development of its next-generation pipeline (new drug candidates).

Conducts 5 billion won Third-Party Allotment Capital Increase... Loading ‘Ammo’ for Next-Generation Pipeline Development

According to the electronic disclosure system on the 12th, Ensol Bio decided to conduct a third-party private placement worth 4,999,995,540 won to secure operating funds. Through this capital increase, 487,329 new common shares will be issued. The issue price per share is 10,260 won.

The purpose of this fundraising is clear. With the commercialization of its flagship pipeline—treatments for degenerative disc disease and osteoarthritis—imminent, the move appears aimed at proactively securing clinical trial costs and operating funds for its next-generation products: the Alzheimer’s treatment “M1K” and the triple-negative breast cancer (TNBC) treatment “C1K.”

The allottee was determined to be Smart & Growth Co., Ltd., a corporation controlled by CEO Hyung In-woo, the company’s largest shareholder. CEO Hyung, who previously played a key role in driving the early growth of Alteogen Inc.(196170), has once again demonstrated to the market his strong confidence in the value of Ensol Bio’s next-generation pipeline by participating in this capital increase.

CEO Hyung’s side has already invested approximately 60 billion won. This additional capital injection is seen as further solidifying the company’s control structure while completely resolving the financial uncertainties facing the company ahead of its IPO. The new shares are scheduled to be listed on July 10. All shares will be subject to a mandatory lock-up period for one year from the date of issuance.

This overwhelming support from the capital markets stems from Ensol Bio’s unrivaled technological capabilities. A prime example is P2K (known as SB-01 in the U.S.), a treatment for degenerative disc disease that was licensed to U.S.-based Spine Biopharma. This pipeline was recently highlighted as the future of spinal treatment by Dr. Jeffrey Ro, a renowned spinal surgeon who appeared on the popular U.S. podcast *The Loop Way*.

Dr. Ro commented, “This peptide (amino acid complex) therapy, which overcomes the iatrogenic damage inflicted on patients by large-incision surgery and reverses disc degeneration with a single needle, is revolutionary.”

Dr. Ro predicted that SB-01 is highly likely to become the standard of care and expressed such strong confidence that he even expressed a willingness to participate in the clinical trial himself. P2K is currently preparing to resume its U.S. Phase 3 clinical trial in the second half of this year. According to Market Insights, a global market research firm, the global degenerative disc disease market is projected to grow to $50 billion (approximately 69 trillion won) by 2030.

Phase 3 Clinical Trial Begins for Knee Osteoarthritis Treatment E1Corporation... Setting Sights on a “1 Trillion Won” Valuation

E1K (Engedi 1000), a treatment for knee osteoarthritis and another key pillar of the company’s strategy, has entered the commercialization countdown after initiating the first patient dosing (PFI) in a Phase 3 clinical trial in South Korea this month. E1K aims to be a disease-modifying osteoarthritis drug (DMOAD) that goes beyond simply relieving pain to structurally improve cartilage. Derived through NGeneBio Co., Ltd.’s proprietary artificial intelligence (AI) platform, ESAIDD, this compound incorporates “signal pathway selective modulation” (SSM) technology that selectively blocks only the pathological signals of transforming growth factor-beta 1 (TGF-β1).

The recent 1000억 won exclusive domestic licensing agreement signed with LEADERS COSMETICS CO.,LTD., a mid-sized Korean pharmaceutical company, serves as a milestone demonstrating E1Corporation’s value. Considering that the Korean market accounts for less than 1% of the global market, the value of global licensing rights is projected to exceed at least 1 trillion won. In particular, the company has secured a final response to its Pre-IND (Pre-Investigational New Drug) application from the U.S. Food and Drug Administration (FDA), thereby establishing regulatory guidelines for entering Phase 3 clinical trials in the U.S., which further enhances the potential for a major technology export.

Based on the achievements of its flagship pipeline, NGeneBio Co., Ltd. will resubmit its application for a technology evaluation to transfer its listing to KOSDAQ in the third quarter. Last year, the company faced rejection due to the review committee’s conservative stance toward new modalities (treatment methods). However, its fundamentals have completely changed this year.

The company has completed preparations to resume the U.S. Phase 3 trial for P2K, realized contract revenue of 1000억 won for E1Corporation, and secured development funds for its next-generation pipeline (Alzheimer’s and breast cancer treatments) through this rights offering. With both financial strength and technological capabilities in place, the market anticipates that this renewed listing attempt will proceed smoothly without any major setbacks.

An Ensol Bio official emphasized, “The major shareholder’s additional investment demonstrates confidence in the company’s future value and the success of our new drugs,” adding, “We will leap forward as a global engine for new drugs that transform the lives of patients worldwide.”